United Therapeutics FDA Accepts Tyvaso sNDA for IPF
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
Silver Spring, Maryland & Research Triangle Park, North Carolina — August 17, 2026 United Therapeutics Corporation announced the full...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 29, 2026 United Therapeutics Corporation announced that the complete results...
SILVER SPRING, Maryland & RESEARCH TRIANGLE PARK, North Carolina, July 2, 2026 United Therapeutics Corporation has announced the acquisition...
